SLRX Salarius Pharmaceuticals Inc: רווח למניה לשנה מתגלגלת

The development of drugs for rare oncological diseases is independent of market cycles, relying instead on medical necessity. The relative change in EPS YoY (ttm) confirms this specificity, where 67.50 captures the current state of the parameter. Salarius Pharmaceuticals (SLRX) possesses authority in creating safe targeted therapies. However, the company remains at a pre-commercial stage, where the expansion of research leads to a proportional increase in R&D expenses.
SLRX (Salarius Pharmaceuticals): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This metric measures the dynamics of the rolling annual earnings per share, allowing for the real-time tracking of market expectations through daily data updates. For Salarius Pharmaceuticals (SLRX), this indicator is critical due to the dependency of its market capitalization on the results of sarcoma inhibitor tests. Analyzing the historical EPS YoY growth over the last 12 months reveals the market's reaction to liquidity shortages. Sharp peaks on the chart often precede corrections. Avoid buying at the indicator's peaks.